CAMBRIDGE, MA -- MAY 22, 2001 -- MedPanel executives today announced the closing of its Series-B funding, with over $1,000,000 raised. The new funds will be used to rapidly advance technology for its new website, hire key personnel, expand sales and marketing efforts.
"These new resources will provide current and future pharmaceutical and biotechnology clients with faster and more precise access to the current thinking of physician opinion leaders," said Will Febbo, Chief Executive Officer, MedPanel, Inc. "This substantial funding round closed quickly. This is further proof that our proprietary approaches to generate qualitative primary research for clients are right on target."About MedPanel, Inc.
MedPanel offers an innovative service that brings focus groups and advisory board activities online in a threaded discussion format, providing advantages over traditional market research methodologies. MedPanel's large key opinion leader database and its online masked participation allows for geographic dispersity without the travel, encouraging participation from experts that would otherwise not be willing or able to participate.
Founded in 1999, MedPanel works with pharmaceutical, biotechnology and medical device companies and the marketing, communications agencies, and financial groups who support them. Clients include Aventis, Bayer AG, Boston Scientific Corporation, GlaxoSmithKline, GelTex Pharmaceuticals, Hollister Inc., Eli Lilly and Company, Millennium Pharmaceuticals, and Pfizer Inc.
MedPanel is a privately held company headquartered in Cambridge, Massachusetts.
Contact: Erin Sheehan 617-661-8080 x29